

# MEA Colorectal Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 220 pages | Data Bridge Market Research

## **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

## Report description:

Middle East and Africa colorectal cancer diagnostics market is projected to register a substantial CAGR of 6.9% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

#### Market Segmentation:

Middle East and Africa Colorectal Cancer Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Stool Examination, Blood Test, Imaging Test, Tumor Markers, Biopsy, and Others), Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, and Others), Age Group (Geriatric, Adults, and Pediatric), End User (Hospital, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030

Some of the factors that can affect the growth of the market are:

- Rise in healthcare expenditure for cancer diagnosis and treatment
- Novel technological advancements in cancer diagnostics

## Market Players:

The key market players in Middle East and Africa colorectal cancer diagnostics market are listed below:

- Koninklijke Philips N.V.
- Quest Diagnostics Incorporated
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- FUJIFILM Corporation
- Agilent Technologies, Inc.
- BD
- General Electric Company
- Siemens Healthcare GmbH

Scotts International, EU Vat number: PL 6772247784

- Abbott
- Neusoft Corporation
- BioFire Diagnostics
- QIAGEN
- Hologic, Inc.
- PlexBio
- GE HealthCare.

## **Table of Contents:**

TABLE OF CONTENTS

- 1 INTRODUCTION 43
- 1.1 OBJECTIVES OF THE STUDY 43
- 1.2 MARKET DEFINITION 43
- 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET 43
- 1.4 LIMITATIONS 45
- 1.5 MARKETS COVERED 45
- 2 MARKET SEGMENTATION 48
- 2.1 MARKETS COVERED 48
- 2.2 GEOGRAPHICAL SCOPE 49
- 2.3 YEARS CONSIDERED FOR THE STUDY 50
- 2.4 CURRENCY AND PRICING 50
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
- 2.6 MULTIVARIATE MODELLING 54
- 2.7 PRODUCT TYPE LIFELINE CURVE 54
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
- 2.9 DBMR MARKET POSITION GRID 56
- 2.10 MARKET END USER COVERAGE GRID 57
- 2.11 VENDOR SHARE ANALYSIS 58
- 2.12 SECONDARY SOURCES 59
- 2.13 ASSUMPTIONS 59
- 3 EXECUTIVE SUMMARY 60
- 4 PREMIUM INSIGHTS 63
- 4.1 PORTER'S FIVE FORCES 64
- 4.2 PESTEL ANALYSIS 65
- 5 INDUSTRY INSIGHTS: 66
- 6 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS 67
- 6.1 REGULATORY SCENARIO IN THE U.S 67
- 6.2 REGULATORY SCENARIO IN AUSTRALIA 67
- 6.3 REGULATORY SCENARIO IN JAPAN 68
- 6.4 REGULATORY SCENARIO IN CHINA 68
- 7 MARKET OVERVIEW 70
- 7.1 DRIVERS 72
- 7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER 72
- 7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS. 72

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 72
- 7.2 RESTRAINTS 73
- 7.2.1 STRINGENT REGULATORY POLICIES 73
- 7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS. 73
- 7.3 OPPORTUNITIES 74
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 74
- 7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 75
- 7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 75
- 7.4 CHALLENGES 76
- 7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 76
- 7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 77
- 8 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 78
- **8.1 OVERVIEW 79**
- 8.2 INSTRUMENTS 82
- 8.2.1 PATHOLOGY-BASED INSTRUMENTS 83
- 8.2.1.1 PCR INSTRUMENTS 83
- 8.2.1.2 SLIDE STAINING SYSTEMS 83
- 8.2.1.3 TISSUE PROCESSING SYSTEMS 84
- 8.2.1.4 CELL PROCESSORS 84
- 8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 84
- 8.2.2 IMAGING INSTRUMENTS 84
- 8.2.2.1 ULTRASOUND SYSTEMS 84
- 8.2.2.2 CT SYSTEMS 84
- 8.2.2.3 MRI SYSTEMS 85
- 8.2.2.4 OTHERS 85
- 8.2.3 BIOPSY INSTRUMENTS 85
- 8.2.4 OTHERS 85
- 8.3 CONSUMABLES & ACCESSORIES 85
- 8.3.1 KITS 86
- 8.3.1.1 PCR KITS 86
- 8.3.1.2 DNA POLYMERASE KITS 86
- 8.3.1.3 NUCLEIC ACID ISOLATION KITS 86
- 8.3.1.4 OTHERS 87
- 8.3.2 REAGENTS 87
- 8.3.2.1 ASSAYS 87
- 8.3.2.2 BUFFERS 87
- 8.3.2.3 PRIMERS 87
- 8.3.2.4 OTHERS 87
- 8.3.3 OTHER CONSUMABLES 87
- 9 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE 88
- 9.1 OVERVIEW 89
- 9.2 STOOL EXAMINATION 92
- 9.3 BLOOD TEST 92
- 9.3.1 COMPLETE BLOOD COUNT (CBC) 93
- 9.3.2 TUMOR MARKER TEST 94
- 9.3.3 LIVER ENZYME BLOOD TEST 94
- 9.4 IMAGING TEST 94

- 9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 95
- 9.4.2 MRI 95
- 9.4.3 ULTRASOUND 95
- 9.4.4 POSITION EMISSION TOMOGRAPHY (PET) 96
- 9.4.5 OTHERS 96
- 9.5 TUMOR MARKERS 96
- 9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA) 97
- 9.5.2 CA19-9 BIOMARKER TEST 97
- 9.5.3 CA 50 MARKER TEST 97
- 9.5.4 OTHERS 97
- 9.6 BIOPSY 97
- 9.7 OTHERS 98
- 10 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 99
- 10.1 OVERVIEW 100
- 10.2 STAGE III 103
- 10.3 STAGE IV 103
- 10.4 STAGE II 104
- 10.5 STAGE I 105
- 10.6 STAGE 0 105
- 11 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP 107
- 11.1 OVERVIEW 108
- 11.2 GERIATRIC 111
- 11.3 ADULTS 111
- 11.4 PEDIATRIC 112
- 12 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 114
- 12.1 OVERVIEW 115
- 12.2 ADENOCARCINOMA 118
- 12.3 COLORECTAL LYMPHOMA 118
- 12.4 GASTROINTESTINAL STROMAL TUMORS 119
- 12.5 CARCINOID TUMORS 120
- 12.6 OTHERS 120
- 13 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER 122
- 13.1 OVERVIEW 123
- 13.2 HOSPITALS 126
- 13.3 DIAGNOSTIC CENTERS 126
- 13.4 CANCER RESEARCH CENTERS 127
- 13.5 AMBULATORY SURGICAL CENTERS 128
- 13.6 ACADEMIC INSTITUTES 128
- 13.7 OTHERS 129
- 14 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION 131
- 14.1 MIDDLE EAST AND AFRICA 132
- 14.1.1 SOUTH AFRICA 142
- 14.1.2 SAUDI ARABIA 147
- 14.1.3 U.A.E. 152
- 14.1.4 EGYPT 157
- 14.1.5 ISRAEL 162
- 14.1.6 REST OF MIDDLE EAST AND AFRICA 167

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 168
- 15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 168
- 16 SWOT ANALYSIS 169
- 17 COMPANY PROFILE 170
- 17.1 F. HOFFMANN- LA ROCHE LTD 170
- 17.1.1 COMPANY SNAPSHOT 170
- 17.1.2 REVENUE ANALYSIS 170
- 17.1.3 COMPANY SHARE ANALYSIS 171
- 17.1.4 PRODUCT PORTFOLIO 171
- 17.1.5 RECENT DEVELOPMENT 171
- 17.2 KONINKLIJKE PHILIPS N.V. 172
- 17.2.1 COMPANY SNAPSHOT 172
- 17.2.2 REVENUE ANALYSIS 172
- 17.2.3 COMPANY SHARE ANALYSIS 173
- 17.2.4 PRODUCT PORTFOLIO 173
- 17.2.5 RECENT DEVELOPMENT 173
- 17.3 THERMO FISHER SCIENTIFIC INC. 175
- 17.3.1 COMPANY SNAPSHOT 175
- 17.3.2 REVENUE ANALYSIS 175
- 17.3.3 COMPANY SHARE ANALYSIS 176
- 17.3.4 PRODUCT PORTFOLIO 176
- 17.3.5 RECENT DEVELOPMENT 176
- 17.4 ILLUMINA, INC. 177
- 17.4.1 COMPANY SNAPSHOT 177
- 17.4.2 REVENUE ANALYSIS 177
- 17.4.3 COMPANY SHARE ANALYSIS 178
- 17.4.4 PRODUCT PORTFOLIO 178
- 17.4.5 RECENT DEVELOPMENT 178
- 17.5 QUEST DIAGNOSTICS INCORPORATED 179
- 17.5.1 COMPANY SNAPSHOT 179
- 17.5.2 REVENUE ANALYSIS 179
- 17.5.3 COMPANY SHARE ANALYSIS 180
- 17.5.4 PRODUCT PORTFOLIO 180
- 17.5.5 RECENT DEVELOPMENT 180
- 17.6 ABBOTT 181
- 17.6.1 COMPANY SNAPSHOT 181
- 17.6.2 REVENUE ANALYSIS 181
- 17.6.3 PRODUCT PORTFOLIO 182
- 17.6.4 RECENT DEVELOPMENT 182
- 17.7 AGILENT TECHNOLOGIES, INC. 183
- 17.7.1 COMPANY SNAPSHOT 183
- 17.7.2 REVENUE ANALYSIS 183
- 17.7.3 PRODUCT PORTFOLIO 184
- 17.7.4 RECENT DEVELOPMENT 184
- 17.8 BD 185
- 17.8.1 COMPANY SNAPSHOT 185
- 17.8.2 REVENUE ANALYSIS 185

- 17.8.3 PRODUCT PORTFOLIO 186
- 17.8.4 RECENT DEVELOPMENT 186
- 17.9 BEIJING O&D BIOTECH CO., LTD. 187
- 17.9.1 COMPANY SNAPSHOT 187
- 17.9.2 PRODUCT PORTFOLIO 187
- 17.9.3 RECENT DEVELOPMENT 187
- 17.10 BIOFIRE DIAGNOSTICS 188
- 17.10.1 COMPANY SNAPSHOT 188
- 17.10.2 REVENUE ANALYSIS 188
- 17.10.3 PRODUCT PORTFOLIO 189
- 17.10.4 RECENT DEVELOPMENT 189
- 17.11 BIO-RAD LABORATORIES, INC. 190
- 17.11.1 COMPANY SNAPSHOT 190
- 17.11.2 REVENUE ANALYSIS 190
- 17.11.3 PRODUCT PORTFOLIO 191
- 17.11.4 RECENT DEVELOPMENT 191
- 17.12 CANON MEDICAL SYSTEMS CORPORATION. 192
- 17.12.1 COMPANY SNAPSHOT 192
- 17.12.2 REVENUE ANALYSIS 192
- 17.12.3 PRODUCT PORTFOLIO 193
- 17.12.4 RECENT DEVELOPMENT 193
- 17.13 FONAR CORP. 194
- 17.13.1 COMPANY SNAPSHOT 194
- 17.13.2 REVENUE ANALYSIS 194
- 17.13.3 PRODUCT PORTFOLIO 195
- 17.13.4 RECENT DEVELOPMENT 195
- 17.14 FUJIFILM CORPORATION 196
- 17.14.1 COMPANY SNAPSHOT 196
- 17.14.2 REVENUE ANALYSIS 196
- 17.14.3 PRODUCT PORTFOLIO 197
- 17.14.4 RECENT DEVELOPMENT 197
- 17.15 GE HEALTHCARE. 198
- 17.15.1 COMPANY SNAPSHOT 198
- 17.15.2 REVENUE ANALYSIS 198
- 17.15.3 PRODUCT PORTFOLIO 199
- 17.15.4 RECENT DEVELOPMENT 199
- 17.16 HOLOGIC, INC. 200
- 17.16.1 COMPANY SNAPSHOT 200
- 17.16.2 REVENUE ANALYSIS 200
- 17.16.3 PRODUCT PORTFOLIO 201
- 17.16.4 RECENT DEVELOPMENT 201
- 17.17 MEDONICA CO. LTD 202
- 17.17.1 COMPANY SNAPSHOT 202
- 17.17.2 PRODUCT PORTFOLIO 202
- 17.17.3 RECENT DEVELOPMENT 202
- 17.18 MERCK KGAA 203
- 17.18.1 COMPANY SNAPSHOT 203

- 17.18.2 REVENUE ANALYSIS 203
- 17.18.3 PRODUCT PORTFOLIO 204
- 17.18.4 RECENT DEVELOPMENT 204
- 17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 205
- 17.19.1 COMPANY SNAPSHOT 205
- 17.19.2 PRODUCT PORTFOLIO 205
- 17.19.3 RECENT DEVELOPMENT 205
- 17.20 MYRIAD GENETICS, INC. 206
- 17.20.1 COMPANY SNAPSHOT 206
- 17.20.2 REVENUE ANALYSIS 206
- 17.20.3 PRODUCT PORTFOLIO 207
- 17.20.4 RECENT DEVELOPMENT 207
- 17.21 NEUSOFT CORPORATION 208
- 17.21.1 COMPANY SNAPSHOT 208
- 17.21.2 REVENUE ANALYSIS 208
- 17.21.3 PRODUCT PORTFOLIO 209
- 17.21.4 RECENT DEVELOPMENT 209
- 17.22 PLEXBIO 210
- 17.22.1 COMPANY SNAPSHOT 210
- 17.22.2 PRODUCT PORTFOLIO 210
- 17.22.3 RECENT DEVELOPMENT 210



Print this form

To place an Order with Scotts International:

☐ - Complete the relevant blank fields and sign

# MEA Colorectal Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 220 pages | Data Bridge Market Research

elect license	License			Price
	Single User License			\$3500.00
	Corporate Users License			\$4200.00
				VAT otal
			·	
ease circle the relev	ant license option. For any question	ons please contact support@	oscotts-international.com or 0048 6	03 394 346.
			companies who are unable to provid	
	,	,		
mail*		Phone*		
rst Name*		Last Name*		
b title*				
ompany Name*		EU Vat / Tax ID	EU Vat / Tax ID / NIP number*	
ddress*		City*		
44.655		Country*		
ip Code*				
		Date	2025-06-26	